Compare BioNano Genomics Inc (BNGO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs PubMatic Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while PubMatic Inc trades at $17.41 (market cap $804.41M). The key difference: PubMatic Inc is far larger — about 58.9× BioNano Genomics Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PUBM | |
|---|---|---|
Market Cap | $13.66M | $804.41M |
Sector | Health | Technology |
52-Week High | $4.92 | $17.78 |
52-Week Low | $1.06 | $6.28 |
Enterprise Value | $16.26M | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
PubMatic (PUBM) trades at $17.76, down slightly by 0.11% today. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth and a significant EPS surprise. The company is focusing on high-margin segments like mobile app and CTV advertising, supported by new AI product launches and executive appointments.
The outlook is cautiously optimistic with a consensus price target of $20.83, implying 17% upside. However, risks include persistent net losses, a high P/E ratio of 132, and competitive pressures in digital advertising. Analyst sentiment is split evenly between Buy and Hold ratings, reflecting uncertainty around near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
